ORC-144
Acute Postoperative Pain / Pain Management
Key Facts
About Orcosa
Orcosa is a private, pre-revenue biotech developing a next-generation drug delivery platform called RITe™. The technology enables tablets that disintegrate in under three seconds in the buccal cavity, aiming to improve drug absorption, speed of onset, and patient compliance, particularly for those with swallowing difficulties. The company's most advanced candidate, ORC-144, is in Phase 1/2 trials for acute postoperative pain, positioning Orcosa in the large and growing market for non-opioid pain therapeutics and novel drug delivery systems. Leadership has bolstered the team with key appointments like a Chief Medical Officer, and the company maintains its own cGMP manufacturing facility in New Jersey.
View full company profile